Stock 688046 GEMPHARMATECH CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials GemPharmatech Co., Ltd.

Equities

688046

CNE100005964

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 16/05/2024 BST 		5-day change 1st Jan Change
11.65 CNY +1.48% Intraday chart for GemPharmatech Co., Ltd. -7.39% -42.18%
04-26 GemPharmatech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-03 Tranche Update on GemPharmatech Co., Ltd.'s Equity Buyback Plan announced on December 27, 2023. CI

Valuation

Fiscal Period: December 2022 2023 2024 2025
Capitalization 1 9,860 4,776 4,776 -
Enterprise Value (EV) 1 9,860 8,262 4,776 4,776
P/E ratio 57.3 x 51.7 x 23.3 x 17.7 x
Yield - 0.79% 0.43% 0.64%
Capitalization / Revenue 19.1 x 13.3 x 6.21 x 4.73 x
EV / Revenue 19.1 x 13.3 x 6.21 x 4.73 x
EV / EBITDA 45 x 37.9 x 16.5 x 13 x
EV / FCF - - 79,608,333 x 85,294,643 x
FCF Yield - - 0% 0%
Price to Book 4.99 x 3.89 x 2.08 x 1.87 x
Nbr of stocks (in thousands) 410,000 410,000 410,000 -
Reference price 2 24.05 11.65 11.65 11.65
Announcement Date 27/02/23 23/02/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025
Net sales 1 516.5 622.2 769 1,009
EBITDA 1 219.2 218.2 290 368.2
EBIT 1 174 160.9 220.8 294
Operating Margin 33.68% 25.86% 28.71% 29.15%
Earnings before Tax (EBT) 1 173.7 158.6 219.8 293.5
Net income 1 164.6 159 207.5 269.9
Net margin 31.87% 25.55% 26.98% 26.76%
EPS 2 0.4200 0.3900 0.5000 0.6600
Free Cash Flow - - 60 56
FCF margin - - 7.8% 5.55%
FCF Conversion (EBITDA) - - 20.69% 15.21%
FCF Conversion (Net income) - - 28.92% 20.75%
Dividend per Share 2 - 0.1600 0.0500 0.0750
Announcement Date 27/02/23 23/02/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2024 Q1
Net sales 1 157.1
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 29.48
Net margin 18.77%
EPS -
Dividend per Share -
Announcement Date 27/04/24
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025
Net Debt - - - -
Net Cash position - - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - - 60 56
ROE (net income / shareholders' equity) 10.6% 7.76% 9.23% 10.5%
ROA (Net income/ Total Assets) 7.31% 6.56% 7.91% 9.02%
Assets 1 2,254 2,422 2,623 2,994
Book Value Per Share 2 4.820 5.180 5.600 6.250
Cash Flow per Share 2 0.2600 0.2800 0.5500 0.8000
Capex 1 190 206 157 145
Capex / Sales 36.82% 33.08% 20.35% 14.34%
Announcement Date 27/02/23 23/02/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for GemPharmatech Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.65 CNY
Average target price
21.13 CNY
Spread / Average Target
+81.40%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GEMPHARMATECH CO., LTD. Stock GemPharmatech Co., Ltd.
-42.18% 661M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.09% 42.12B
LONZA GROUP AG Stock Lonza Group AG
+49.62% 42.05B
CELLTRION, INC. Stock Celltrion, Inc.
-4.96% 29.18B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.18% 26.02B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.95% 18.9B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+8.61% 13.21B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.73% 12.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.31% 12.16B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-6.26% 11.42B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 688046 Stock
  4. Financials GemPharmatech Co., Ltd.